Method comparison for CA 15-3, CA 19-9, and CA 125 determination using the new loci technique of dimension Vista 1500 and Immulite 2000 XPI

Journal of Immunoassay and Immunochemistry

Volumn 33, Issue 4, 2012, Pages 435-445

  Zur, Berndt ^a   Holdenrieder, Stefan ^a   Albers, Eike ^a   Walgenbach Brnagel, Gisela ^a   Stoffel Wagner, Birgit ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

biomarker; cancer; clinical chemistry; evaluation; imprecision

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

CA-125 ANTIGEN; CA-19-9 ANTIGEN; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MUCIN-1; OXYGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84866401255     PISSN: 15321819     EISSN: 15324230     Source Type: Journal    
DOI: 10.1080/15321819.2012.666221     Document Type: Article

References (20)

1. Stieber, P.; Heinemann, V. Sensible use of tumor markers. J. Lab. Med. 2008, 32, 339-360.
2. Sturgeon, C. M.; Hoffman, B. R.; Chan, D. W.; Ch'ng, S. L.; Hammond, E.; Hayes, D. F.; Liotta, L. A.; Petricoin, E. F.; Schmitt, M.; Semmes, O. J.; Söletormos, G.; van der Merwe, E.; Diamandis, E. P. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: Quality requirements. Clin. Chem. 2008, 54(8), e1-e10.
3. Hilkens, J.; Kroezen, V.; Buijs, F.; Hilgers, J.; van Vielt, M.; de Voogd, W.; Bonfer, J.; Bruning, P. F. MAM-6, a carcinoma assiociated marker; preliminary characterization and detection in sera of breast cancer patients. In Monoclonal Antibodies and Breast Cancer; Ceriani, R. L.; Ed.; Martinus Nijoff: The Hague, 1985, 28-42.
4. Hayes, D. F.; Sekine, H.; Ohno, T.; Abe, M.; Keefe, K.; Kufe, D. W. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J. Clin. Invest. 1985, 75, 1671-1678. (Pubitemid 15039493)
5. Sturgeon, C. M.; Duffy, M. J.; Stenman, U. H.; Lilja, H.; Brünner, N.; Chan, D. W.; Babaian, R.; Bast, R. C., Jr.; Dowell, B.; Esteva, F. J.; Haglund, C.; Harbeck, N.; Hayes, D. F.; Holten-Andersen, M.; Klee, G. G.; Lamerz, R.; Looijenga, L. H.; Molina, R.; Nielsen, H. J.; Rittenhouse, H.; Semjonow, A.; Shih, I. E. M.; Sibley, P.; Sölétormos, G.; Stephan, C.; Sokoll, L.; Hoffman, B. R.; Diamandis, E. P. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem. 2008, 54(12), e11-79. (Pubitemid 352777353)
6. Tondini, C.; Hayes, D. F.; Kufe, D. W. Circulating tumor markers in breast cancer. Hematol. Oncol. Clin. North Am. 1989, 3, 653-674. (Pubitemid 20016119)
7. Ruibal, A.; Genolla, J.; Rosell, M.; Gris, J. M.; Colomer, R. Serum CA 15-3 levels in patients with non-tumoral diseases, and established of a threshold for tumoral activity: Results in 1219 patients. Int. J. Biol. Markers 1986, 1, 159-160.
8. Magnani, J. L.; Nilsson, B.; Brockhaus, M.; Zopf, D.; Steplewski, Z.; Koprowski, H.; Ginsburg, V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer in a ganglioside containing sialylated lacto-N-fucopentaose II. J. Biol. Chem. 1982, 257, 14365-14369. (Pubitemid 13141316)
9. Lamerz, R. CA 19-9, GICA (gastrointestinal cancer antigen). In Serological Cancer Markers; Sell, S. Ed.; Humana Press: New York, 1992, 309-339.
10. Boeck, S.; Haas, M.; Laubender, R. P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, H.; Mansmann, U.; Heinemann, V. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin. Cancer Res. 2010, 16, 986-994.
11. Sturgeon, C. M.; Duffy, M. J.; Hofmann, B. R.; Lamerz, R.; Fritsche, H. A.; Gaarenstroom, K.; Bonfrer, J.; Ecke, T. H.; Grossman, H. B.; Hayes, P.; Hoffmann, R. T.; Lerner, S. P.; Löhe, F.; Louhimo, J.; Sawczuk, I.; Taketa, K.; Diamandis, E. P. National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin. Chem. 2010, 56(6), e1-48.
12. O'Brian, T. J.; Beard, J. B.; Underwood, L. J.; Dennis, R. A.; Santin, A. D.; York, L. The CA 125 gene: An extracellular superstructure dominated by repeat sequences. Tumor Biol. 2001, 22, 348-366. (Pubitemid 34062947)
13. Kobayashi, F.; Sagawa, N.; Nanbu, Y.; Nakamura, K.; Nonogaki, M.; Ban, C.; Fujii, S.; Mori, T. Immunohistochemical localization and tissue levels of tumor-associated glycoproteins CA 125 and CA 19-9 in the deciduas and fetal membranes at various gestational ages. Am. J. Obstet. Gynecol. 1989, 160, 1232-1238. (Pubitemid 19144500)
14. Clinical and Laboratory Standards Institute=NCCLA. Protocols for Determination of Limits of Detection an Limits of Quantitation; Approved Guideline. CLSI=NCCLA document EP-17-A. ISBN: 1-56238-551-8, 2004.
15. Ullman, E. F.; Kirakossian, H.; Switchenko, A. G.; Ishkanian, J.; Ericson, M.; Wartchow, C. A.; Piro, M.; Pease, J.; Irvin, B. R.; Singh, S.; Patel, R.; Dafforn, A.; Davalian, D.; Skold, C.; Kurn, N.; Wagner, D. B. Luminescent oxygen channelling assay (LOCI): Sensitive, broadly applicable homogenous immunoassay method. Clin. Chem. 1996, 42, 1518-1526. (Pubitemid 26300260)
16. Christenson, R. H.; Cervelli, D. R.; Sterner, J.; Bachmann, L. M.; Rebuck, H.; Gray, J.; Kelley, W. E. Analytical performance and clinical concordance of the cancer biomarkers CA 15-3, CA 19-9, CA 125 II, carcinoembryonic antigen, and alpha fetoprotein on the Dimension Vista System. Clin. Biochem. 2011, 44, 1128-1136.
17. Molina, R.; Gion, M.; Gressner, A.; Troalen, F.; Auge, J. M.; Holdenrieder, S.; Zancan, M.; Wycislo, M.; Stieber, P. Alternative antibodies for the detection of CA15-3 antigen: An European Multicenter Study for the evaluation of the analytical and clinical performance of the Access1 BR Monitor Assay on Beckman Coulter's UniCel1 DxI 800 immunoassay system. Clin. Chem. Lab. Med. 2008, 46, 612-622. (Pubitemid 351749114)
18. Stieber, P.; Molina, R.; Gion, M.; Gressner, A.; Troalen, F.; Holdenrieder, S.; Auge, J. M.; Zancan, M.; Wycislo, M.; Jarrige, V. Alternative antibody for the detection of CA19-9 antigen: A European Multicenter Study for the evaluation of the analytical and clinical performance of the Access1 GI Monitor Assay on the UniCel1 DxI 800 Immunoassay System from Beckman Coulter. Clin. Chem. Lab. Med. 2008, 46, 600-611. (Pubitemid 351749108)
19. Holdenrieder, S.; Molina, R.; Gion, M.; Gressner, A.; Troalen, F.; Auge, J. M.; Zancan, M.; Wycislo, M.; Stieber, P. Alternative antibodies for the detection of CA125 antigen: An European Multicenter Study for the evaluation of the analytical and clinical performance of the Access1 OV Monitor Assay on Beckman Coulter's UniCel1 DxI 800 immunoassay system. Clin. Chem. Lab. Med. 2008, 46, 588-599. (Pubitemid 351749107)
20. Mongia, S. K.; Rawlins, M. L.; Owen, W. E.; Roberts, W. L. Performance characteristics of seven automated CA 125 assays. Am. J. Clin. Pathol. 2006, 125, 921-927. (Pubitemid 43801543)